Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23949886 | 1.00 | KMT2A (0.47) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL28120493 | 0.87 | KMT2A (0.46) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL30342988 | 0.84 | KMT2A (0.43) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL30342992 | 0.84 | KMT2A (0.43) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL10564876 | 0.83 | KMT2A (0.51) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL9121966 | 0.83 | KMT2A (0.51) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL3080042 | 0.83 | KMT2A (0.51) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL12744032 | 0.83 | TSHR (0.56) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL12552579 | 0.82 | CA1 (0.43) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL14587572 | 0.82 | TBXAS1 (0.49) | KMT2ACA1CA2LTA4HEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513234-B2 | HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087419-A1 | HIV INTEGRASE INHIBITORS | POLB, CCNB1, POLR2A | KMT2A 1215/4885HTT 4741/4885CA1 4176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.